Skip to content

STAT6-IP reduces the development of allergic-type lung inflammation and airway hyperresponsiveness

Pulmonary research group in Canada: the Meakins-Christie Laboratories

Dr. Elizabeth Fixman and Dr. Brian Ward (IDIGH Program at RI-MUHC) co-authored a study in the Journal of Leukocyte Biology demonstrating that STAT6-IP reduces the development of allergic-type lung inflammation and airway hyperresponsiveness in mice re-challenged with respiratory syncytial virus (RSV). (February 2017)

Sew research published in the Journal of Leukocyte Biology suggests that a peptide developed to inhibit a key regulator of asthma responses reduces development of inflammation and ‘twitchy’ airways in mice.

Read the full press release

Scientists discover peptide that could reduce the incidence of RSV-related asthma. EurekAlert AAAS. Feb 1, 2017.

Read the publication:

Bharat T. Srinivasa, Katherine H. Restori, Jichuan Shan, Louis Cyr, Li Xing, Soojin Lee, Brian J. Ward, and Elizabeth D. Fixman. STAT6 inhibitory peptide given during RSV infection of neonatal mice reduces exacerbated airway responses upon adult reinfection. J Leukoc Biol. 2017 Feb;101(2):519-529.